Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
25000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-05-01
Study Completion Date
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overarching aim of this nationwide Swedish cohort study is to reduce death and suffering from oesophageal and gastric tumours. This aim can be accomplished by a broad research approach that aims to identify:
1. Risk factors and preventive actions
2. Early detection
3. Improved treatment
1. Risk factors and preventive actions
2. Early detection
3. Improved treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Swedish Esophageal and Cardia Cancer Study
NCT06031155
Oesophageal Cancer
Surgery
Survivorship
+1 more
ACTIVE_NOT_RECRUITING
Effects of a Training Intervention After Thoracoabdominal Oesophagus Surgery
NCT02335970
Oesophagus Cancer
COMPLETED
NA
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
NCT01089803
Squamous Cell Carcinoma
Laryngeal Cancer
COMPLETED
Outcomes of A Novel Treatment Decision of Patients With Esophageal and Head and Neck Carcinoma Synchronously
NCT03450447
Head and Neck Cancer
Esophageal Cancer Stage
UNKNOWN
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
NCT05432219
Recurrent Nasopharyngeal Carcinoma
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Swedish OEsophageal and GAstric tumour Study (SOEGAS)
Background Globally, oesophageal and gastric tumours are common with a high mortality. Oesophageal cancer and gastric cancer combined are often labelled upper gastrointestinal (GI) cancer. These tumours share many characteristics, including anatomy, risk factors, treatment and prognosis.
The main known risk factors for adenocarcinoma of the oesophagus and gastro-oesophageal junction are gastro-oesophageal reflux disease and obesity. The main risk factors for the other main histological type of oesophageal cancer, squamous cell carcinoma, are tobacco smoking and alcohol. The strongest known risk factor for gastric cancer is infection with Helicobacter pylori. Shared risk factors include dietary factors, tobacco smoking and heredity.
The curative treatment of upper GI cancers builds heavily on demanding surgery, where most of the oesophagus or stomach is resected. Except for surgery, most tumours are also treated with pre-operative, and sometimes postoperative, chemotherapy or chemoradiotherapy (6). The palliative treatment is also very important since the majority of patients are not eligible for curative treatment.
The survival is poor in patients diagnosed with upper GI cancer. This is mainly explained by late diagnosis since the symptoms are usually late and aggressive tumour biology, with early spread and recurrence. If detected early, the prognosis is excellent, but only a fraction of patients is detected at early tumour stages. The overall 5-year survival in oesophageal cancer is less than 20% and in gastric cancer it is less than 30% in most populations, including Sweden. The rate of patients found eligible for curative treatment including surgery is only 20-35%. Among operated patients the postoperative 5-year survival is 30-50%. It is crucial to conduct research that can improve the lives also of palliative patients.
It is of great importance to identify factors that can prevent upper GI cancer. Means to facilitate the detection at a premalignant or early and curable tumour stage would improve the prognosis and survivorship. It is also highly relevant to identify factors that can improve the curative and palliative treatment.
Resources Opportunities Sweden offers internationally unique possibilities to link high quality registry data with clinical data from medical records, which make up a fantastic resource for valid research in aetiology, prevention, detection, and treatment of upper GI cancer. The personal identity numbers assigned to all Swedish residents enables individual data to be linked.
Experience Our research group has a long track record in addressing risk factors, preventive measures and treatment of upper GI cancer. The research group contains expertise in clinics, epidemiology and biostatistics.
Overarching aims
The overarching aim of this research project is to reduce death and suffering from upper GI cancer. This aim can be accomplished by a broad research approach that aims to identify:
1. Risk factors and prevention Preventive actions can decrease the incidence of these tumours.
2. Early detection Early detection provides great opportunities for local treatment (endoscopic resection). Detection at an early invasive stage before metastases have occurred also provides good chances of cure, but requires more extensive surgery.
3. Improved treatment The mainstay treatment for cure in upper GI cancer is surgical resection. The research assessing how the surgery can become optimised is limited.
Specific aims
1. Evaluate the recent incidence trends
These analyses will separately assess differences in incidence over time across various patient and tumour characteristics, including:
* Sex
* Age
* Tumour stage
* Tumour histology
* Tumour site within the oesophagus or stomach
2. Identify risk factors
* Medications
* Lifestyle factors
* Reproductive factors
* Perinatal factors
* Other diseases and co-morbidities
* Surgical procedures for other indications than upper GI tumours
* Hereditary factors
* Socio-economic factors
* Dental and oral health
* Other factors
3. Identify factors that facilitate early detection
* Lifestyle factors
* Other diseases and co-morbidities
* Hereditary factors
* Socio-economic factors
4. Evaluate trends in prognosis Treatment Curative Surgery Neo-adjuvant therapy
Palliative
Patient characteristics Sex Age BMI Socio-economic factors
Tumour characteristics Stage Histology Site within the oesophagus or stomach
5. Identify factors that can improve prognosis and survivorship
* Tumour characteristics
* Surgical factors
* Neoadjuvant therapy
* Socio-economic factors
* Lifestyle factors
* Other diseases and co-morbidities
* Previous surgical procedures
* Reproductive factors
* Medications
* Dental and oral health
* Other factors
Methods Study cohort The cohort is entitled the Swedish OEsophageal and GAstric tumour Study (acronym SOEGAS), and will include patients diagnosed with oesophageal or gastric tumour from year 2000 onwards. The selection of the cohort will be based on a diagnosis code representing oesophageal or gastric tumours recorded in: Swedish Cancer Registry, Swedish Patient Registry or Cause of Death Registry.
Data collection
This cohort needs to be linked with additional data for us to be able to evaluate the specific research aims listed above. The resources and data are needed for all cohort members:
1. The Swedish Patient Registry ('Patientregistret') since 1987 when this registry became nationwide complete. This registry is managed by the National Board of Health and Welfare (SoS by Swedish acronym). These data are needed for evaluation of surgical procedures, re-operations, and all comorbidities.
2. The Swedish Cancer Registry ('Cancerregistret') since 1958 when this registry was initiated. This registry is managed by SoS. Detailed data are needed for the oesophageal or gastric tumours, including date of diagnosis, exact tumour site, histological type of tumour, and tumour stage. Data are also needed on previous cancers before the start date of the cohort (year 2000) as well as any concurrent or later (secondary) tumours.
3. The Swedish Prescribed Drug Registry ('Läkemedelsregistret') since July 2005 when this registry started. This registry is managed by SoS. We need these data to assess medications as risk factors for these tumours, to assess how medications influence the outcomes in patients diagnosed with these tumours, and also to assess comorbidities.
4. The Swedish Dental Health Registry ('Tandhälsoregistret') since this registry was started in 2008. This registry is held by SoS. We need these data to assess whether dental and oral health influences the risk of developing oesophageal and gastric tumours as well as the prognosis and survivorship in these patients.
5. Swedish Medical Birth Registry ('Medicinska födelseregistret') since it started in 1973. This registry is held by SoS, and from this registry we can assess data on paternity and other key variables in women who have given birth, e.g. BMI. We also need data on the children, e.g. gestational age, small for gestational age, large for gestational age, preterm birth.
6. The Swedish Causes of Death Registry ('Dödsorsaksregistret') since 1st January 2000. This registry is managed by SoS, and is required to assess date of death and causes of death. These data are needed for the prognostic studies and also for censoring of patients no longer at risk of various outcomes under study.
7. The Swedish Multi-Generation Registry ('Flergenerationsregistret') since its start. This registry is held by SCB, and these data are needed to assess the role of heredity in the aetiology of these tumours.
8. The Swedish Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym) ('Longitudinell integrationsdatabas för sjukförsäkrings- och arbetsmarknadsstudier'). This registry is held by SCB and is needed for data on socio-economic factors, including highest level of education, cohabitation, civil status, income, country of birth and parental countries of birth, latest year of immigration and emigration, and place of residence.
9. The Swedish Registry of the Total Population ('Registret över totalbefolkningen') since 1968. These data are needed to calculate the expected risk of oesophageal and gastric tumours in the corresponding background population. This registry is also needed for updated information on civil status, divorce, emigration, immigration, cohabitation and updated information about date of death.
10. The Swedish Defence Recruitment Agency ('Mönstringsregistret') since its initiation. We need data on BMI and physical capacity from this registry.
11. Medical records. We need data from the hospitals regarding clinical factors including tumour stage, treatment, risk factors, and various treatment factors. This means that we need to have personal identity numbers for all cohort members to be able to find the relevant medical records.
12. Total population data. Finally, we need data from the Swedish Registry of the Total Population ('Registret över totalbefolkningen') and the Swedish Cancer Registry from the entire Swedish population from year 2000 onwards to calculate the expected incidence and mortality rates in the corresponding background population.
Personal identity numbers and key codes We need the personal identity numbers of the selected cohort members to retrieve the medical records from the healthcare services. We also need the National Board of Health and Welfare ('Socialstyrelsen') to keep the key codes to all cohort members in order for us to ask for up-dates of the cohort regarding potential needs for additional time, follow-up, cohort size and further data.
Statistical analysis The statistical analysis will be done by one of our senior biostatisticians employed in the group. All data management and analyses will be done according to laws and regulations. There will be various statistical methods used and these need to be tailored for each individual study based on the cohort. However, studies evaluating risk factors will typically be analysed using multivariable logistic regression, providing odds ratios and 95% confidence intervals adjusted for potential confounding factors. Studies evaluating mortality as the outcome will be analysed using multivariable Cox regression, providing hazard ratios and 95% confidence intervals adjusted for potential confounding factors.
Statistical power The cohort will be powerful enough to study the main research questions. We cannot expand the study further while maintaining its high internal validity. It is already nationwide complete and the study period from 2000 onwards mirrors a modern era of treatment. Thus, we cannot increase the sample size.
Specific study protocols The study protocol for each study included in this project will be specified with detailed study protocols before initiated. This project plan does not allow detailed presentation of all future studies based on the data collection, but it gives an overview of the topic.
Significance
SOEGAS has all prerequisites to contribute substantially with new knowledge that might reduce deaths and suffering in oesophageal and gastric tumours on a global scale. All of the studies included in the project will be based on Swedish data and we have good reasons to believe that outputs from the project will have a global influence as well. The quality and the contents of the Swedish registries might have changed over calendar periods but from 2000 onwards only limited changes have been made, which improves the quality of the research and facilitates interpretations and reduces various sources of bias. Taken together, SOEGAS might bring extremely valuable information to an area of research which is clearly understudied which is the aetiology, prevention and treatment of tumours of the oesophagus and stomach.
Background Globally, oesophageal and gastric tumours are common with a high mortality. Oesophageal cancer and gastric cancer combined are often labelled upper gastrointestinal (GI) cancer. These tumours share many characteristics, including anatomy, risk factors, treatment and prognosis.
The main known risk factors for adenocarcinoma of the oesophagus and gastro-oesophageal junction are gastro-oesophageal reflux disease and obesity. The main risk factors for the other main histological type of oesophageal cancer, squamous cell carcinoma, are tobacco smoking and alcohol. The strongest known risk factor for gastric cancer is infection with Helicobacter pylori. Shared risk factors include dietary factors, tobacco smoking and heredity.
The curative treatment of upper GI cancers builds heavily on demanding surgery, where most of the oesophagus or stomach is resected. Except for surgery, most tumours are also treated with pre-operative, and sometimes postoperative, chemotherapy or chemoradiotherapy (6). The palliative treatment is also very important since the majority of patients are not eligible for curative treatment.
The survival is poor in patients diagnosed with upper GI cancer. This is mainly explained by late diagnosis since the symptoms are usually late and aggressive tumour biology, with early spread and recurrence. If detected early, the prognosis is excellent, but only a fraction of patients is detected at early tumour stages. The overall 5-year survival in oesophageal cancer is less than 20% and in gastric cancer it is less than 30% in most populations, including Sweden. The rate of patients found eligible for curative treatment including surgery is only 20-35%. Among operated patients the postoperative 5-year survival is 30-50%. It is crucial to conduct research that can improve the lives also of palliative patients.
It is of great importance to identify factors that can prevent upper GI cancer. Means to facilitate the detection at a premalignant or early and curable tumour stage would improve the prognosis and survivorship. It is also highly relevant to identify factors that can improve the curative and palliative treatment.
Resources Opportunities Sweden offers internationally unique possibilities to link high quality registry data with clinical data from medical records, which make up a fantastic resource for valid research in aetiology, prevention, detection, and treatment of upper GI cancer. The personal identity numbers assigned to all Swedish residents enables individual data to be linked.
Experience Our research group has a long track record in addressing risk factors, preventive measures and treatment of upper GI cancer. The research group contains expertise in clinics, epidemiology and biostatistics.
Overarching aims
The overarching aim of this research project is to reduce death and suffering from upper GI cancer. This aim can be accomplished by a broad research approach that aims to identify:
1. Risk factors and prevention Preventive actions can decrease the incidence of these tumours.
2. Early detection Early detection provides great opportunities for local treatment (endoscopic resection). Detection at an early invasive stage before metastases have occurred also provides good chances of cure, but requires more extensive surgery.
3. Improved treatment The mainstay treatment for cure in upper GI cancer is surgical resection. The research assessing how the surgery can become optimised is limited.
Specific aims
1. Evaluate the recent incidence trends
These analyses will separately assess differences in incidence over time across various patient and tumour characteristics, including:
* Sex
* Age
* Tumour stage
* Tumour histology
* Tumour site within the oesophagus or stomach
2. Identify risk factors
* Medications
* Lifestyle factors
* Reproductive factors
* Perinatal factors
* Other diseases and co-morbidities
* Surgical procedures for other indications than upper GI tumours
* Hereditary factors
* Socio-economic factors
* Dental and oral health
* Other factors
3. Identify factors that facilitate early detection
* Lifestyle factors
* Other diseases and co-morbidities
* Hereditary factors
* Socio-economic factors
4. Evaluate trends in prognosis Treatment Curative Surgery Neo-adjuvant therapy
Palliative
Patient characteristics Sex Age BMI Socio-economic factors
Tumour characteristics Stage Histology Site within the oesophagus or stomach
5. Identify factors that can improve prognosis and survivorship
* Tumour characteristics
* Surgical factors
* Neoadjuvant therapy
* Socio-economic factors
* Lifestyle factors
* Other diseases and co-morbidities
* Previous surgical procedures
* Reproductive factors
* Medications
* Dental and oral health
* Other factors
Methods Study cohort The cohort is entitled the Swedish OEsophageal and GAstric tumour Study (acronym SOEGAS), and will include patients diagnosed with oesophageal or gastric tumour from year 2000 onwards. The selection of the cohort will be based on a diagnosis code representing oesophageal or gastric tumours recorded in: Swedish Cancer Registry, Swedish Patient Registry or Cause of Death Registry.
Data collection
This cohort needs to be linked with additional data for us to be able to evaluate the specific research aims listed above. The resources and data are needed for all cohort members:
1. The Swedish Patient Registry ('Patientregistret') since 1987 when this registry became nationwide complete. This registry is managed by the National Board of Health and Welfare (SoS by Swedish acronym). These data are needed for evaluation of surgical procedures, re-operations, and all comorbidities.
2. The Swedish Cancer Registry ('Cancerregistret') since 1958 when this registry was initiated. This registry is managed by SoS. Detailed data are needed for the oesophageal or gastric tumours, including date of diagnosis, exact tumour site, histological type of tumour, and tumour stage. Data are also needed on previous cancers before the start date of the cohort (year 2000) as well as any concurrent or later (secondary) tumours.
3. The Swedish Prescribed Drug Registry ('Läkemedelsregistret') since July 2005 when this registry started. This registry is managed by SoS. We need these data to assess medications as risk factors for these tumours, to assess how medications influence the outcomes in patients diagnosed with these tumours, and also to assess comorbidities.
4. The Swedish Dental Health Registry ('Tandhälsoregistret') since this registry was started in 2008. This registry is held by SoS. We need these data to assess whether dental and oral health influences the risk of developing oesophageal and gastric tumours as well as the prognosis and survivorship in these patients.
5. Swedish Medical Birth Registry ('Medicinska födelseregistret') since it started in 1973. This registry is held by SoS, and from this registry we can assess data on paternity and other key variables in women who have given birth, e.g. BMI. We also need data on the children, e.g. gestational age, small for gestational age, large for gestational age, preterm birth.
6. The Swedish Causes of Death Registry ('Dödsorsaksregistret') since 1st January 2000. This registry is managed by SoS, and is required to assess date of death and causes of death. These data are needed for the prognostic studies and also for censoring of patients no longer at risk of various outcomes under study.
7. The Swedish Multi-Generation Registry ('Flergenerationsregistret') since its start. This registry is held by SCB, and these data are needed to assess the role of heredity in the aetiology of these tumours.
8. The Swedish Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym) ('Longitudinell integrationsdatabas för sjukförsäkrings- och arbetsmarknadsstudier'). This registry is held by SCB and is needed for data on socio-economic factors, including highest level of education, cohabitation, civil status, income, country of birth and parental countries of birth, latest year of immigration and emigration, and place of residence.
9. The Swedish Registry of the Total Population ('Registret över totalbefolkningen') since 1968. These data are needed to calculate the expected risk of oesophageal and gastric tumours in the corresponding background population. This registry is also needed for updated information on civil status, divorce, emigration, immigration, cohabitation and updated information about date of death.
10. The Swedish Defence Recruitment Agency ('Mönstringsregistret') since its initiation. We need data on BMI and physical capacity from this registry.
11. Medical records. We need data from the hospitals regarding clinical factors including tumour stage, treatment, risk factors, and various treatment factors. This means that we need to have personal identity numbers for all cohort members to be able to find the relevant medical records.
12. Total population data. Finally, we need data from the Swedish Registry of the Total Population ('Registret över totalbefolkningen') and the Swedish Cancer Registry from the entire Swedish population from year 2000 onwards to calculate the expected incidence and mortality rates in the corresponding background population.
Personal identity numbers and key codes We need the personal identity numbers of the selected cohort members to retrieve the medical records from the healthcare services. We also need the National Board of Health and Welfare ('Socialstyrelsen') to keep the key codes to all cohort members in order for us to ask for up-dates of the cohort regarding potential needs for additional time, follow-up, cohort size and further data.
Statistical analysis The statistical analysis will be done by one of our senior biostatisticians employed in the group. All data management and analyses will be done according to laws and regulations. There will be various statistical methods used and these need to be tailored for each individual study based on the cohort. However, studies evaluating risk factors will typically be analysed using multivariable logistic regression, providing odds ratios and 95% confidence intervals adjusted for potential confounding factors. Studies evaluating mortality as the outcome will be analysed using multivariable Cox regression, providing hazard ratios and 95% confidence intervals adjusted for potential confounding factors.
Statistical power The cohort will be powerful enough to study the main research questions. We cannot expand the study further while maintaining its high internal validity. It is already nationwide complete and the study period from 2000 onwards mirrors a modern era of treatment. Thus, we cannot increase the sample size.
Specific study protocols The study protocol for each study included in this project will be specified with detailed study protocols before initiated. This project plan does not allow detailed presentation of all future studies based on the data collection, but it gives an overview of the topic.
Significance
SOEGAS has all prerequisites to contribute substantially with new knowledge that might reduce deaths and suffering in oesophageal and gastric tumours on a global scale. All of the studies included in the project will be based on Swedish data and we have good reasons to believe that outputs from the project will have a global influence as well. The quality and the contents of the Swedish registries might have changed over calendar periods but from 2000 onwards only limited changes have been made, which improves the quality of the research and facilitates interpretations and reduces various sources of bias. Taken together, SOEGAS might bring extremely valuable information to an area of research which is clearly understudied which is the aetiology, prevention and treatment of tumours of the oesophagus and stomach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Oesophageal Cancer
Gastric Cancer
Surgical Treatment
Aetiology
Prognostic Factors
Survival
Prediction
Treatment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SWEGASS
Gastric cancer patients.
Surgery
Intervention Type
PROCEDURE
Patients who undergo surgery are separately assessed
SESS
Oesophageal cancer patients.
Surgery
Intervention Type
PROCEDURE
Patients who undergo surgery are separately assessed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgery
Patients who undergo surgery are separately assessed
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
\-
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johannes Asplund
UNKNOWN
Sponsor Role
collaborator
Fredrik Mattsson
UNKNOWN
Sponsor Role
collaborator
Eivind Gottlieb
UNKNOWN
Sponsor Role
collaborator
Wilhelm Leijonmarck
UNKNOWN
Sponsor Role
collaborator
Ivan Ernudd
UNKNOWN
Sponsor Role
collaborator
Ellinor Lundberg
UNKNOWN
Sponsor Role
collaborator
Sheraz Markar
UNKNOWN
Sponsor Role
collaborator
Giola Santoni
UNKNOWN
Sponsor Role
collaborator
Karolinska Institutet
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jesper Lagergren
Professor of Surgery
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jesper Lagergren, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska Institutet
Stockholm, , Sweden
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xie SH, Santoni G, Bottai M, Gottlieb-Vedi E, Lagergren P, Lagergren J. Prediction of conditional survival in esophageal cancer in a population-based cohort study. Int J Surg. 2023 May 1;109(5):1141-1148. doi: 10.1097/JS9.0000000000000347.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOEGAS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Observational Study to Compare Effectiveness and Safety of the Surgeries in Patients With Esophageal Cancer
NCT03428074
COMPLETED
Textbook Outcomes After Oesophagectomy in Regional Australia
NCT06721715
NOT_YET_RECRUITING
Treatment Outcomes of Esophageal Cancer
NCT05177393
RECRUITING
Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
NCT04443478
RECRUITING
RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY
NCT05570487
UNKNOWN
Esophagectomy With or Without Prior Ischemic Gastric Preconditioning
NCT02457299
TERMINATED
NA
Rehabilitation and Recovery for Persons with Esophageal or Gastric Cancer
NCT05698992
RECRUITING
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
NCT01048281
RECRUITING
Esophageal Stump Washout
NCT01980394
COMPLETED
NA
KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
NCT02205463
WITHDRAWN
PHASE1
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
NCT04455282
RECRUITING
Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)
NCT00149266
TERMINATED
PHASE3
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
NCT01858805
COMPLETED
IMaC - Immune Pathways in Oesophagogastric Cancer
NCT06057220
NOT_YET_RECRUITING
Genetic and Environmental Risk Factors Related to Esophageal Cancer
NCT01035398
ACTIVE_NOT_RECRUITING
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
NCT06061705
RECRUITING
NA
Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer
NCT04871204
COMPLETED
PHASE2
Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?
NCT00583934
COMPLETED
An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma
NCT05341479
UNKNOWN
Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma
NCT03404921
COMPLETED
NA
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
NCT06289374
RECRUITING
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00022139
COMPLETED
PHASE2
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
NCT00193141
COMPLETED
PHASE2